Criteria for the award includes a client's workers' compensation policy loss ratio, workers' compensation experience modification (EMR), and BLS/DART/OSHA recordable incident rate.  BB&T Insurance Services recognizes only those companies with outstanding overall safety performance and awards those who have commendable, outstanding, and excellent performance.   

"GreenWood, Inc. sets high standards for safety performance and we're proud to recognize them with this safety award,' says Warren Blanchard, BB&T Insurance Services.  'They are consistent in their commitment to safety which is instilled in their workplace culture.  It is our pleasure to support GreenWood with their accident prevention and claim management initiatives, and we gladly recognize them for these extraordinary results.'  

Mike Simmons, Corporate Safety Director for GreenWood adds, 'We are honored to earn this award from BB&T and it is a privilege to have received it every year since the initiation of the program.  It's a direct result of our employees placing safety first as the foundation for all our project work at GreenWood.  By maintaining open communications with our teams to reinforce safety standards, we are able to consistently perform work in the safest manner possible for our customers.' 

About GreenWood, Inc.

GreenWood provides integrated maintenance, operations and construction solutions designed to extend the life of critical assets, influence operational efficiencies and deliver bottom line improvements for plants and facilities throughout the Southeast and Mid-Atlantic.  We operate under a 'Customer-Centered' philosophy where safety performance is always first and our flexibility to respond to customer needs is an ongoing priority.  For more information, visit www.GreenWoodInc.com.
 
#             #             #

— WebWireID176207 —

Focus on High Amines and Improved Profitability

Tosoh is shutting down its oldest ethyleneamine production line. That line began operations in 1967 and has an annual capacity of 18,000 metric tons, the largest percentage of which is the low-profitability low amine EDA. The old line will permanently cease operating in August 2013.

Tosoh's two remaining lines together provide the company with an annual ethyleneamine production capacity of 71,000 metric tons. Specifically, the two lines yield a higher percentage of high amines than the old line slated for termination. They are thus better aligned with Tosoh as an EDC process-based supplier to focus strategically on the production and sale of high amines while also making efforts to cut costs and improve the profitability of ethyleneamines overall.

Ethyleneamines are commonly used as building blocks in the chemical synthesis of products with value-added features. They and their derivatives are widely used in epoxy hardeners, wet-strength resins for paper, chelates, pharmaceutical and agrochemical intermediates, and other industrial chemicals.

EDA and similar grades have low molecular weights and are called low amines, while high molecular weight amines, such as diethylenetriamine (DETA) and triethylenetetramine (TETA) are called high amines. Among those of Tosoh's high amine products popular in Japan and overseas are triethylenediamine (TEDA) and Toyocat catalysts for polyurethane production. To stay ahead of the competition, Tosoh seeks to maintain strong or dominant positions in selective markets by continually shifting toward more competitive and profitable high-grade products.

TOSOH CORPORATION

WHO WE ARE

Tosoh Corporation is a Japanese chemical company established in 1935 and listed on the First Section of the Tokyo Stock Exchange. It is the parent of the Tosoh Group, which comprises 132 companies worldwide and a multiethnic workforce of over 11,000 people and generated net sales of ¥668.5 billion (US$7.4 billion at the year-end rate of ¥90.45 to the US dollar) in fiscal 2013, ended March 31, 2013.

WHAT WE DO

Tosoh is one of the largest chlor-alkali manufacturers in Asia. The Company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh's petrochemical operations supply ethylene, polymers, and polyethylene, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases, such as diabetes and certain cancers, and to prevent epidemics by identifying pathogenic microbes. In addition, Tosoh develops products and provides services to purify water and to monitor the environment as part of a commitment to a sustainable future.

Stock Exchange Ticker Symbol: JP: 4042

Disclaimer

This document contains forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. The forward-looking statements are also identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements.

— WebWireID176194 —

The CRBOH sets standards for professional competence for occupational hygienists and occupational hygiene technologists. According to the CRBOH, RM points represent attainment and maintenance of a high standard of professionalism.

The Advanced Fungal and Data Interpretation Workshop will be held on Thursday, August 22, 2013 in Toronto, Canada from 9:00 AM to 5:00 PM. The workshop will be held at the Holiday Inn Toronto Downtown Centre located at 30 Carlton St. Toronto, ON M5B 2E9. The cost of the workshop is $299 per person.

'Through this workshop attendees will gain an understanding of advanced sampling techniques for fungi, interpret data, and apply them to investigative strategies,' states Michael Menz, Environmental Training Manager at EMSL Analytical, Inc. 'EMSL Analytical provides a complete array of Microbiology Laboratory Testing services at our equipped and accredited laboratories throughout the United States and Canada."

To view more details about this workshop, including a workshop agenda and continuing education credits, please download the PDF or visit our website.

To register, please contact Angela Elias at 1-888-958-8170.

To learn more about EMSL's Laboratory services or for upcoming workshops, please visit www.EMSL.com, email  info@EMSL.com , or call (800) 220-3675.

About EMSL Analytical, Inc.
EMSL Analytical is the nation's leading testing laboratory with over 30 locations throughout theUnited StatesandCanada. We are a nationally recognized and locally focused provider specializing in consumer product, environmental, industrial hygiene, indoor air quality, microbiology, radon, food, and materials testing services to professionals and the general public. Please visit our website for a complete listing of accreditations from leading organizations, as well as state and federal regulating bodies.

— WebWireID176140 —

— WebWireID176077 —

Three major wildfires burned in Colorado over the weekend, but the Black Forest fire has been classified as the most destructive on record in the state. In addition to 750 firefighters battling the flames, aircrafts are flying low and dropping flame-retardant chemicals. The military and national guard also joined in to fight against the fast moving fire.

When large amounts of smoke are released from a wildfire, the air becomes filled with combustion by-products such as soot, ash, and char. The smoke can travel long distances and cause damaging effects on properties and human health.

'Often times, property owners of smoke damaged properties have to show proof of damage before insurance providers will approve any repairs and remediation work on a property,' states EMSL's Materials Testing Laboratory Manager, Eugenia Mirica, Ph. D., 'EMSL Analytical is the nation's leading provider of smoke damage testing services and offers fire debris analysis to help settle insurance claims for property damage caused by a wildfire.'

To learn more about testing for smoke damage, char, carbon black, soot, indoor air quality (IAQ), or other environmental issues, please visit www.EMSL.com, call (800) 220-3675, or email info@EMSL.com .

About EMSL Analytical, Inc.
EMSL Analytical is a nationally recognized and locally focused provider of consumer product, environmental, industrial hygiene, food, and materials testing services to professionals and the general public. In addition, the company offers a large variety of air sampling equipment, sampling cassettes, and monitoring equipment. The company has an extensive list of accreditations from leading organizations, as well as state and federal regulating bodies. They include, but are not limited to AIHA IHLAP, AIHA EMLAP, AIHA ELLAP, A2LA, NVLAP, CDC Elite, CPSC (Consumer Product Safety Commission), CA ELAP, NY ELAP, TX Department of State Health Services, and multiple other state accrediting agencies.

— WebWireID176067 —

-Two new air separation units to be built in Dzerzhinsk

-One-stop shop for engineering and gas supply services

Munich, - – Technology company The Linde Group will be managing the gas supply infrastructure of SIBUR, the largest petrochemical company in Russia, CIS and Eastern Europe, at its Dzerzhinsk site in the Nizhny Novgorod region of Russia, also building and operating two new air separation units (ASUs). Both companies signed a long-term contract to this effect today. Under the deal, Linde will be investing EUR 70 million in the ASUs. The new on-site plants are set to come on stream at the end of 2015.

'We are delighted to build further on our long-standing, successful relationship with SIBUR through this new project,' said Professor Dr Aldo Belloni, Member of the Executive Board of Linde AG. 'This on-site deal bears further testimony to the success of our integrated business model. Our customers can rely on us for a one-stop service covering both the delivery of turnkey petrochemical plants and the enabling gas supplies.'

'This deal will enhance the operational efficiency of SIBUR's ethylene oxide and glycols plants in Dzerzhinsk and enable us to further strengthen our leading positions in Russia and CIS markets,' commented Valery Andosov, Director for Strategy, SIBUR's Plastics and Organic Synthesis Division. 'We are glad to execute this deal with Linde, a long-time and well-established partner for SIBUR. The new unit will supply industrial gases not only to SIBUR's plant in Dzerzhinsk but also to other businesses. By outsourcing industrial gas supply, SIBUR will be able to focus on developing its core operations,' said Sergey Merzlyakov, Managing Director – Head of Plastics and Organic Synthesis business unit at SIBUR.

In an initial step, Linde will assume responsibility for SIBUR's four ASUs in Dzerzhinsk and modernise these plants in order to increase energy efficiency. As part of the next step, Linde's Engineering Division will build two new ASUs, which – on completion – will be operated by Linde's Gases Division. They will have a total production capacity of around 30,000 normal cubic metres of gaseous oxygen per hour (Nm3/h). The main aim of the new ASUs is to supply the oxygen, nitrogen and compressed air required for SIBUR's local ethylene oxide and glycols plants.

Linde will also use the plants to supply air gases to other customers at the Dzerzhinsk chemicals hub via an extended pipeline network. In addition, it will deliver liquid oxygen, nitrogen and argon to the regional market in Nizhny Novgorod and beyond.

Linde is currently engaged in two other projects with SIBUR at its Tobolsk site in Western Siberia. In June 2012, Linde won a licensing and Front End Engineering Design (FEED) contract for one of the world's largest ethylene plants. At Tobolsk, Linde also constructed a polypropylene plant, with an annual capacity of 500,000 tonnes, which is currently being put into operation.

About The Linde Group

The Linde Group is a world-leading gases and engineering company with around 62,000 employees in more than 100 countries worldwide. In the 2012 financial year, Linde generated revenue of EUR 15.280 bn. The strategy of the Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

For more information, see The Linde Group online at www.linde.com

— WebWireID176063 —

By the end of this year, more than 50% of this major project is expected to be built, for which around 800 to 1,000 workers are being hired per month. By December, the construction project will boast approximately 10,000 workers. When ready, Braskem Idesa will have annual installed production capacity of 1 million tons of polyethylene. Total investment in the project is US$4.5 billion, with 75% coming from Braskem and 25% from the Idesa Group.

— WebWireID176062 —

Basel, - -Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy. Current treatment options for malignant glioma are limited, and Avastin represents the first new medicine approved worldwide for newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer, in the last eight years.

'This approval of Avastin is important news for people in Japan who have been diagnosed with glioma and glioblastoma because aggressive brain cancer can significantly reduce a person's quality of life and the ability to perform everyday activities,' said Hal Barron MD, Roche's Chief Medical Officer and Head of Global Product Development. 'People with newly diagnosed glioblastoma who received Avastin plus radiotherapy and temozolomide chemotherapy in the pivotal study experienced a significantly longer period of time without their cancer worsening.'

The approval was based on data from three clinical studies in GBM:

-The phase II BRAIN study
-A Japanese phase II study (JO22506)
-The pivotal phase III AVAglio study, which demonstrated that when Avastin was added to standard treatment, patients lived significantly longer without their disease getting worse.

Final results from the AVAglio study in newly diagnosed GBM patients were recently presented at the 49th annual meeting of the American Society of Clinical Oncology in Chicago.

Applications for first-line treatment have been filed with the health authorities in the EU and Switzerland. Avastin is marketed in Japan by Chugai Pharmaceutical, a member of the Roche Group. Avastin for malignant glioma was designated as an orphan drug in Japan in May 2013, as the estimated number of newly diagnosed malignant glioma and GBM patients per year is about 1,700.

About the AVAglio study

AVAglio is a phase III, randomised, double-blind, placebo controlled trial that assessed the efficacy and safety profile of Avastin in combination with radiotherapy and temozolomide chemotherapy following surgery or biopsy in patients with newly diagnosed glioblastoma. Patients were randomised to one of two arms:

-Avastin plus radiotherapy and temozolomide chemotherapy for six weeks followed by a four-week break. Patients then received Avastin and temozolomide chemotherapy for up to six cycles, followed by Avastin alone until disease progression.
-Radiotherapy, temozolomide chemotherapy and placebo for six weeks followed by a four-week break. Patients then received temozolomide chemotherapy and placebo for up to six cycles, followed by placebo until disease progression.

AVAglio study results

-Avastin plus radiotherapy and temozolomide chemotherapy significantly reduced the risk of the glioblastoma worsening or death by 36 percent compared to radiotherapy and temozolomide chemotherapy plus placebo (PFS as assessed by trial investigators, a co-primary endpoint: HR=0.64; p less than 0.0001, median PFS 10.6 months vs. 6.2 months, respectively). People who received Avastin plus radiotherapy and temozolomide chemotherapy did not have a statistically significant improvement in OS (the other co-primary endpoint), compared to those who received radiotherapy and temozolomide chemotherapy plus placebo (HR=0.88; [95% CI 0.76, 1.02], p=0.0987). Median survival was similar in both arms (16.8 moinths vs. 16.7 months, respectively). No new safety findings were observed in the AVAglio study and adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications.
-Health-related quality of life measures including global health status and physical, social and motor functioning, as well as communication deficit, remained stable or improved in most patients in both arms of the trial during the time from diagnosis to disease progression.

About glioblastoma

Glioma (cancer of the glial cells) is the most common type of malignant primary brain tumour (a tumour that originates in the brain), accounting for approximately one third of all cases diagnosed1. Glioblastoma (or glioblastoma multiforme) is the most common and the most aggressive type of glioma1. Globally, the incidence of glioblastoma is approximately 1 to 2 in 100,000 people annually1.2. Current treatment options for GBM are very limited. Generally, patients' tumours get worse within the first 6 months of initial therapy and the median overall survival of patients following diagnosis is 15 months3. Glioblastoma has among the highest levels of vascular endothelial growth factor (VEGF) expression of any solid tumour, which led to the rationale to investigate the effect of anti-angiogenic therapies on this disease.

About Avastin – over nine years of transforming cancer care

With the initial approval in the USA for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced cancer.

Today, Avastin is continuing to transform cancer care through its proven survival benefit (overall survival and/or progression free survival) across several types of cancer. Avastin is approved in Europe for the treatment of advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, and is available in the US for the treatment of colorectal cancer, non-small cell lung cancer and kidney cancer. In addition, Avastin is approved in the US and over 60 other countries worldwide for the treatment of patients with progressive glioblastoma following prior therapy. The approval in the USA was granted under the Food and Drug Administration's (FDA) accelerated approval program. Avastin is approved in Japan for the treatment of the advanced stages of colorectal, non-small cell lung cancer and breast cancer. Avastin is the only anti-angiogenic therapy available for the treatment of these numerous advanced cancer types, which collectively cause over 2.5 million deaths each year.

Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment today. Over one million patients have been treated with Avastin so far. A comprehensive clinical programme with more than 500 ongoing clinical trials is investigating the use of Avastin in over 50 tumour types.

About Avastin – mode of action

An independent blood supply is critical for a tumour to grow beyond a certain size (2mm) and spread (metastasise) to other parts of the body. Tumours develop their own blood supply in a process called angiogenesis by releasing vascular endothelial growth factor (VEGF) – a key driver for tumour growth. Avastin is an antibody that precisely targets and inhibits VEGF. Precise VEGF inhibition by Avastin allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments with limited additional impact on the side effects of these therapies.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

-----
All trademarks used or mentioned in this release are protected by law.

References
1. Central Brain Tumor Registry of the United States (CBTRUS) 2012. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008 (Revised March 23, 2012). Available from: http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf. Last accessed 21 May 2013.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Last accessed 21 May 2013.
3. Stupp R, Mason W, van den Bent M et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005;352:987-96.

— WebWireID176059 —

Financial close of the project financing is expected to occur in the third quarter of this year.

'Securing the financing for this historic project is the achievement of a significant and critical milestone,' said Andrew N. Liveris, Dow's chairman and chief executive officer. 'Sadara is a cornerstone of Dow's growth strategy. The joint venture will introduce a differentiated product slate from a competitive, low-cost position which will transform the landscape of our industry and the chemicals and plastics sector in Saudi Arabia.'

'The response to the Sadara joint venture financing has been very strong,' said Bill Weideman, Dow's executive vice president and chief financial officer. 'This high-quality investment is expected to provide a competitive cost position for the Company, while capturing customer demand in emerging regions and driving high-margin, sustainable global growth.'

The formation of this joint venture is a major step forward in Dow's strategy to drive long-term profitable growth in its downstream, innovation-driven businesses and in fast-growing regions such as Asia Pacific, the Middle East and Africa, and Eastern Europe. The joint venture is expected to deliver EBITDA margins of 35-40 percent and a stream of equity earnings for Dow averaging $500 million annually during the first 10 years following its start-up.

Sadara is building a world-scale, fully integrated chemicals complex in Jubail Industrial City II, Kingdom of Saudi Arabia. The complex will be comprised of 26 manufacturing units, will possess flexible cracking capabilities and is expected to produce more than 3 million metric tons of high-value performance plastics and specialty chemical products. The first production units are expected to come on-line in the second half of 2015, with full production starting in mid-2016.

About Dow

Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company connects chemistry and innovation with the principles of sustainability to help address many of the world's most challenging problems such as the need for clean water, renewable energy generation and conservation, and increasing agricultural productivity. Dow's diversified industry-leading portfolio of specialty chemical, advanced materials, agrosciences and plastics businesses delivers a broad range of technology-based products and solutions to customers in approximately 160 countries and in high growth sectors such as electronics, water, energy, coatings and agriculture. In 2012, Dow had annual sales of approximately $57 billion and employed approximately 54,000 people worldwide. The Company's more than 5,000 products are manufactured at 188 sites in 36 countries across the globe. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com.

®Trademark of The Dow Chemical Company ('Dow') or an affiliated company of Dow

— WebWireID176056 —

UPM Biofibrils are micro- and nanofibrillated cellulose products that can be used for shaping materials and giving them new characteristics. In this collaboration, UPM and Ashland will jointly study the use of biofibrils in a wide range of industrial application opportunities. For example, biofibrils might be used to improve the quality and performance of a broad array of polymer products that include coatings and construction materials, home and car care products, and energy drilling applications.

The collaboration marks a milestone for two companies with extensive expertise in cellulose technology. UPM has pursued research and development of biofibrils technology for several years and has a large portfolio of patent applications and production experience. Ashland has its own research and patents in microfibrillar cellulose technology.

"Our collaborative relationship with UPM provides an excellent opportunity to combine the UPM Biofibrils technology with Ashland's application expertise in order to bring new products and functionalities to our customers," said May Shana'a, vice president, Technology and Growth Strategy, Ashland Specialty Ingredients. "When we combine our strengths and know-how with experts offering new technologies that complement our product lines, we can deliver value-added performance to our customers."

"Innovation is a key component of Ashland's growth strategy, regardless of whether those ideas originate from within the ranks of Specialty Ingredients' 500-person global research team or from selected industry partners," added Walter Solomon, Ashland vice president and chief growth officer. "The most important thing is to take those ideas and develop them into commercially viable products that can help build our customers' businesses."

UPM Biofibrils technology is a result of a long-term research and development commitment. Cornerstones of UPM's Biofore strategy are the versatile use of renewable wood biomass combined with innovation and sustainability.

"UPM Biofibrils is a novel biomaterial that allows development of new fibre-based products with exciting properties for the UPM product portfolio. The collaboration with Ashland's global development team enables further development and commercialization of UPM Biofibrils in several industrial applications," said Esa Laurinsilta, director, UPM Biofibrils.

About UPM

UPM leads the integration of bio and forest industries into a new, sustainable and innovation-driven future. Our products are made of renewable raw materials and are recyclable. UPM consists of three Business Groups: Energy and pulp, Paper, and Engineered materials. The Group employs around 22,000 people. UPM is present in 67 countries and has production units in 17 countries. UPM's annual sales exceed EUR 10 billion. UPM's shares are listed on the Helsinki stock exchange.

UPM - The Biofore Company - www.upm.com

About Ashland

In more than 100 countries, the people of Ashland Inc. (NYSE: ASH) provide the specialty chemicals, technologies and insights to help customers create new and improved products for today and sustainable solutions for tomorrow. Our chemistry is at work every day in a wide variety of markets and applications, including architectural coatings, automotive, construction, energy, food and beverage, personal care, pharmaceutical, tissue and towel, and water treatment. Visit ashland.com to see the innovations we offer through our four commercial units - Ashland Specialty Ingredients, Ashland Water Technologies, Ashland Performance Materials and Ashland Consumer Markets.

— WebWireID176055 —

Because ordinary glass protects against ultraviolet B (UVB) rays, which cause blistering and sunburns, many people do not realize they are still being exposed to harmful UVA rays that penetrate deep into the skin. UVA rays are the same rays that cause auto interiors to fade and crack as time passes. Known as 'sunblock for your car,' LLumar window film adds a protective layer to glass, offering high-quality sun protection. The transparent film blocks up to 99 percent of all harmful ultraviolet rays which penetrate glass, and cause long term, cumulative skin damage.

According to The Skin Cancer Foundation, each year in the United States there are more than 3.5 million new cases of skin cancer. This is more than the combined incidents of breast, prostate, lung and colon cancers.

A 2010 study from the St. Louis University Medical School revealed that nearly 53 percent of skin cancers in the US occur on the left, or drivers' side of the body. Researchers believe the increase in left-sided skin cancers may be from exposure to UVA radiation while driving. The trend reverses to the right side of the body in countries like Australia, where the drivers sit on the right side of the car. According to The Skin Cancer Foundation, 90 percent of all non-melanoma skin cancers are associated with exposure to UV radiation. UVA rays penetrate glass during daylight hours, 365 days a year, even on cloudy days.

In a recent article,* 'Sun Hazards in Your Car,' Susan Butler, MD, a dermatologist and micrographic surgeon at the California Institute, points to a trend in 'wrinkles, leathering, sagging, brown 'age' spots and even skin cancers' on the left side of patient's faces. 'The more time subjects spent driving a vehicle, the more severe their photodamage on the left side.'

'Most parents don't let their kids outside to play without sunscreen, yet they may be exposing them to sun damage every time they are in the car,' says Mark Gershenson, Director, Global LLumar Brand Management at Eastman. 'Installation of window film is relatively inexpensive and you don't have to think about it. For busy parents, this can be a both a timesaver and a relief. ' A typical window film installation ranges from $200-$500 depending on the size of the vehicle and level of film performance chosen.

LLumar automotive window films have earned The Skin Cancer Foundation's Seal of Recommendation, a symbol of safety and efficacy. The Skin Cancer Foundation grants its Seal of Recommendation to products that meet the Foundation's specific criteria for effective UV sun protection.

Installation Options
LLumar window films can be professionally installed at more than 1,100 LLumar and FormulaOne® dealers throughout the United States. They are manufactured in the United States and are backed with a manufacturer's lifetime warranty. Visit www.LLumar.com to find a local dealer. For parents looking for added privacy for passengers and valuables, LLumar films are available in a wide selection of shades.

For more information about the LLumar window films, visit www.LLumar.com/skinprotection. 'Like' LLumar on Facebook to receive skin protection tips at www.facebook.com/LLumarwindowfilm.

Eastman is a manufacturer member of The International Window Film Association (IWFA), a unified industry body of window film dealers, distributors and manufacturers that facilitates the growth of the industry by providing unbiased research, influencing policy and promoting awareness of window film.

* 'The Skin Cancer Foundation's Journal,' May, 2012.

​Eastman is a global specialty chemical company that produces a broad range of products found in items people use every day. With a portfolio of specialty businesses, Eastman works with customers to deliver innovative products and solutions while maintaining a commitment to safety and sustainability. Its market-driven approaches take advantage of world-class technology platforms and leading positions in attractive end-markets such as transportation, building and construction, and consumables. Eastman focuses on creating consistent, superior value for all stakeholders. As a globally diverse company, Eastman serves customers in approximately 100 countries and had 2012 pro forma combined revenues, giving effect to the Solutia acquisition, of approximately $9.1 billion. The company is headquartered in Kingsport, Tennessee, USA and employs approximately 13,500 people around the world. For more information, visit www.eastman.com.

— WebWireID176050 —

Shanghai, China
Air Products (NYSE: APD), a leading global supplier of performance materials, has won the 2013 Ringier Coatings Technology Innovation Awards for its new Airase™ Structured Siloxane Defoamer Line (SSDL™ Defoamers). As a global leader of water-based technology for specialty additives, Air Products has received this prestigious award for the third consecutive year.

The award-winning Airase SSDL Defoamers are a line of formulated, siloxane-based defoamers consisting of seven siloxane defoamers for applications such as paints and coatings, inks, adhesives and other industrial applications. Each Airase SSDL defoamer in the line has a different balance of defoaming strength and formulation compatibility, as well as predictable performance relative to each other, allowing formulators to take a systematic approach to defoamer selection. In addition, the Airase SSDL defoamers are free of hazardous air pollutant (HAP) and alkylphenol ethoxylate (APE) and do not contribute volatile organic compounds (VOCs) to formulations (EPA Method 24). These products also have improved pH stability compared to conventional silicone defoamers and can provide excellent stability and persistency for coatings and ink formulations.

'We are honored to have won the Technology Innovation Award for the third year in a row. It demonstrates Air Products' leading global role in technology innovation and new products development,' said Min Chong, vice president and general manager of Performance Materials Asia for Air Products, at the awards ceremony. 'Air Products has more than 40 years' experience in materials science and surface chemistry. As a pioneer in the shift from solvent to water-based technology, we will continue to develop innovative solutions to help our customers address challenges of waterborne coatings in water-based applications.'

About Ringier Technology Innovation Awards
Launched in 2006, the Ringier Technology Innovation Awards recognize those who have made the most significant contributions for the advancement of industry through technological innovation, increasing productivity, boosting economic efficiency and creating market opportunities. The awards for the coatings industry were set up in 2011. To qualify for the Awards, products must be relevant to China and in the forefront of the international coatings industry, and be judged to have helped take China's coatings industry to new levels.

About Air Products
Air Products (NYSE:APD) provides atmospheric, process and specialty gases; performance materials; equipment; and technology. For over 70 years, the company has enabled customers to become more productive, energy efficient and sustainable. More than 20,000 employees in over 50 countries supply innovative solutions to the energy, environment and emerging markets. These include semiconductor materials, refinery hydrogen, coal gasification, natural gas liquefaction, and advanced coatings and adhesives. In fiscal 2012, Air Products had sales of approaching $10 billion. For more information, visit www.airproducts.com.

NOTE: This release may contain forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's reasonable expectations and assumptions as of the date of this release regarding important risk factors. Actual performance and financial results may differ materially from projections and estimates expressed in the forward-looking statements because of many factors not anticipated by management, including risk factors described in the Company's Form 10K for its fiscal year ended September 30, 2012.

— WebWireID175964 —

As Operations Manager, Ann will be focusing on enduring and strengthening SMC's Logistics Operational Excellence and comes with an extensive background and knowledge in international transportation and supply chain logistics.

About Special Materials Company
SMC, formed in 1996, and headquartered in New York City, is a global specialty chemical company and the largest global marketer of VOC exempts solvents.  It also serves global markets in agriculture, energy, paint and coatings, paper, cosmetics, pharmaceuticals, and intermediates. Currently, it has ownership in 3 factories in China, one in the United States, several distribution centers across the globe as well as sales offices in the USA, Europe, China and South America. It was recently named to the ICIS top 100 Global Chemical Distributors list.

— WebWireID175955 —

Perlon-Monofil GmbH belongs to the High Performance Materials (HPM) business unit of specialty chemicals company LANXESS. It manufactures an extensive range of polyamide and polyester monofilament products for a wide variety of applications, and markets them worldwide under the brand names Perlon, Atlas and Bayco. The plastic wires are used for the production of durable technical fabrics, cords and ropes with outstanding dimensional stability and high strength. Typical applications include rope manufacture, sports fishing, the paper and sports goods industries, and fences, bracings and guy ropes in agriculture. According to supplier data, products from Perlon-Monofil are noted for their weather resistance, strength, elongation properties, load-bearing capacity and overall resistance properties.

LANXESS is a leading specialty chemicals company with sales of EUR 9.1 billion in 2012 and roughly 17,400 employees in 31 countries. The company is currently represented at 50 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of plastics, rubber, intermediates and specialty chemicals. LANXESS is a member of the leading sustainability indices Dow Jones Sustainability Index (DJSI) World and FTSE4Good as well as the Carbon Disclosure Leadership Index (CDLI).

— WebWireID175861 —

'The upgrade process went well and CHAMPS was there to ensure our success,' says Dave Erich, IT Manager at Appvion.  'They provided the initial guidance and framework we needed to get the project started, then remained available as we progressively migrated from site to site.  In doing so, we leaned on them for administrative and user training.'

The upgrade is giving Appvion enhanced functionality that provides a smoother flow and better match for their work processes.  Overall, approximately 150 users across the three sites access the maintenance system routinely to initiate work requests, generate work orders, capture completed work, perform preventive maintenance, and track spare parts usage.

'CHAMPS provides everything we need in a maintenance system,' Erich further stated.  'As a company, CHAMPS is very customer focused and they are fully supportive of our needs.  We value the relationship we have with them and are confident this recent upgrade will keep us current on the latest functionality available.'

Appvion creates product solutions through its development and use of coating formulations, coating applications and Encapsys® microencapsulation technology.  The 106-year-old company produces thermal, carbonless and security papers and Encapsys products, and is 100 percent employee owned.

About CHAMPS Software, Inc.

For more than four decades, CHAMPS Software, Inc. has been developing and delivering Computerized Maintenance Management System (CMMS) and Enterprise Asset Management (EAM) software solutions that enable enterprises of varying size, sophistication, and industry to optimize the life cycles of their capital assets.  CHAMPS CMMS/EAM continuously improves operations by incorporating industry best practices with the flexibility inherent in component based web architected solutions. Regardless of organizational size or geographical layout, CHAMPS CMMS/EAM is purposely scalable to manage business processes for asset optimization across the enterprise.  Efficient acquisition, maintenance, repairs, replacement or salvaging of these critical assets result in operational excellence, leading to decreased cost and increased profits.  For more information, visit www.CHAMPSInc.com.
 
#      #      # 

— WebWireID175829 —

Ungerleider will provide an update on Dow's near-term actions and long-term value-drivers, including the Company's targeted cost, cash, capital, and pricing measures and prioritized R&D. In addition, Ungerleider will provide details on Dow's outlook and priorities.

Dow invites investors to listen to the live webcast of the presentation through its website at www.dow.com/investors/events. A replay of the presentation will also be available on the Company's website within 24 hours following the webcast.

About Dow

Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company connects chemistry and innovation with the principles of sustainability to help address many of the world's most challenging problems such as the need for clean water, renewable energy generation and conservation, and increasing agricultural productivity. Dow's diversified industry-leading portfolio of specialty chemical, advanced materials, agrosciences and plastics businesses delivers a broad range of technology-based products and solutions to customers in approximately 160 countries and in high growth sectors such as electronics, water, energy, coatings and agriculture. In 2012, Dow had annual sales of approximately $57 billion and employed approximately 54,000 people worldwide. The Company's more than 5,000 products are manufactured at 188 sites in 36 countries across the globe. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com.

®TM Trademark of The Dow Chemical Company ('Dow') or an affiliated company of Dow

— WebWireID175820 —

PITTSBURGH, – PPG Industries' (NYSE:PPG) coil and extrusion coatings group announced that it has donated DURANAR® ULTRA-COOL® coatings to the Habitat for Humanity home being constructed as a demostration of affordable sustainability at the American Institute of Architects (AIA) National Conference and Expo in Denver, June 20-22.

The home, which is being built by AIA Denver in partnership with CAD-1, Inc., a Denver-based provider of architectual design software, is seeking to become the first 'green' Habitat for Humanity project to earn LEED® Platinum certification from the U.S. Green Building Council (USGBC).

PPG donated Duranar ULTRA-Cool coatings in Colonial Red for the cool metal roof, which was painted by Berridge Manufacturing, San Antonio, Texas, and installed by Superior Roofing & Architectural Sheet Metal, Aurora, Colo. Duranar ULTRA-Cool coatings are formulated with proprietary ultraviolet (UV)-reflective pigments that enable homes and buildings to stay cooler and help save energy by reducing the need to use air-conditioning systems.

Colonial Red is one of hundreds of colors of Duranar ULTRA-Cool coatings registered with ENERGY STAR® and the Cool Roof Rating Council (CRRC). Because of its exceptional solar reflectivity, the palette of Duranar ULTRA-Cool coatings includes an extensive range of light, medium and dark colors for color roof applications, giving architects the freedom to design in color without sacrificing energy performance.

The Habitat for Humanity home is being constructed by Blue Spruce Habitat for Humanity in Kittredge, Colo., a suburb of Denver, with donated materials and labor. It was designed by Margaret Baldwin Blakely, AIA, Alan Ford, AIA, Kathy Ford, AIA, and Matt Weaver, associate AIA, winners of a Habitat for Humanity of Colorado design-build competition.

For more about Duranar ULTRA-Cool coatings, visit www.ppgideascapes.com or call 1-888-PPG-IDEA (774-4332). To learn more about the Habitat for Humanity home, including scheduled viewing times during the AIA show, visit www.aiadenverdesignbuild.com.

PPG: BRINGING INNOVATION TO THE SURFACE.(TM)
PPG Industries' vision is to continue to be the world's leading coatings and specialty products company. Through leadership in innovation, sustainability and color, PPG helps customers in industrial, transportation, consumer products, and construction markets and aftermarkets to enhance more surfaces in more ways than does any other company. Founded in 1883, PPG has global headquarters in Pittsburgh and operates in nearly 70 countries around the world. Sales in 2012 were $15.2 billion. PPG shares are traded on the New York Stock Exchange (symbol:PPG). For more information, visit www.ppg.com.

----
Bringing innovation to the surface is a trademark and Duranar and ULTRA-Cool are registered trademarks of PPG Industries Ohio, Inc.
ENERGY STAR is a joint trademark of the U.S. Environmental Protection Agency and the U.S. Department of Energy.
LEED – an acronym for the phrase Leadership in Energy and Environmental Design – is a registered trademark of the U.S. Green Building Council.

— WebWireID175818 —

Novo will provide an overview of Air Products and present the company's growth opportunities and leadership positions in key markets and geographies around the world.

An audio webcast and presentation slides will be available on the event details page on Air Products' Investor Relations web site.

About Air Products
Air Products (NYSE:APD) provides atmospheric, process and specialty gases; performance materials; equipment; and technology. For over 70 years, the company has enabled customers to become more productive, energy efficient and sustainable. More than 20,000 employees in over 50 countries supply innovative solutions to the energy, environment and emerging markets. These include semiconductor materials, refinery hydrogen, coal gasification, natural gas liquefaction, and advanced coatings and adhesives. In fiscal 2012, Air Products had sales approaching $10 billion. For more information, visit www.airproducts.com.

— WebWireID175761 —

All required approvals have been secured and relevant documents were signed today in Beijing to finalise the transaction. This sale reflects BHP Billiton's exit from the Browse Joint Ventures.

— WebWireID175749 —

Achim Steiner, UN Under-Secretary-General and Executive Director of the UN Environment Programme (UNEP) welcomed the announcement by the Unites States and Chinese Heads of State announced they would be targeting Hydrofluorocarbons (HFCs) –a group of replacement chemicals for products such as refrigerators and foams for which there are already a range of climate and ozone-friendly alternatives.

'The signal from [President Barack Obama and Chinese President Xi Jinping] is important as both a confidence builder and if it paves the way to a universal agreement involving all nations that reflects the science of where all emissions are today and where they need to be by a series of deadlines beginning with 2020,' said Mr. Steiner said in a press release from UNEP.

The announcement, Mr. Steiner continued 'could signal a new and perhaps transformational chapter in international cooperation on climate change.'

HFCs are beginning to replace another group of chemicals known as HCFCs that damage the ozone layer—the thin gassy layer around the Earth that filters out deadly levels of ultra-violet light from the sun.

UNEP says that while HFCs are ozone-layer friendly they are, however, powerful greenhouse gases: if taken up by industry over the next few years and decades they are likely, by 2050, to amount to emissions equivalent to 3.5 to 8.8 Gigatonnes (Gt) of carbon dioxide.

That is comparable to total current annual emissions from transport, estimated at around 6-7 Gt annually according to a UNEP-coordinated study from 2011.

The US and Chinese leaders said they would work through the Montreal Protocol, the UNEP-hosted treaty established to protect the ozone layer, and the United Nations Framework Convention on Climate Change (UNFCCC) to achieve international action in respect to phasing down the consumption and production of HFCs.

Mr. Steiner said: 'Along with a variety of recent signals from several key countries including China and the United States, this one on HFCs by these two key economies is welcome as the world moves towards a universal UN treaty on climate change by 2015—certainly allowing the market for HFCs to grow will only aggravate the challenge of combating climate change.'

UNEP, in partnership with over 60 countries and organizations, is also working to phase-down some HFCs and other so- called short-lived climate pollutants such as black carbon or 'soot' and methane under a one-year-old initiative called the Climate and Clean Air Coalition (CCAC).

This voluntary Coalition is promoting reduction of short-lived climate pollutants to tackle air pollution, bring widespread benefits for health and agriculture as well as to lead to near-term climate benefits.

While short-lived climate pollutants are responsible for a substantial fraction of near-term climate change, actions on short-term climate pollutants need to be complemented by deep and rapid cuts in CO2 emissions if global mean temperature increase over the 21st Century is to be held below 2°C

'It is widely recognized that securing a meaningful treaty and keeping an average global temperature rise under 2 degrees C this century will require all hands on deck—what, however, must not be overlooked or sidelined is the urgency to also tackle the principal greenhouse gas, carbon dioxide, as part of negotiations underway under the UN Climate Convention,' said Mr. Steiner.

— WebWireID175726 —